Colorado molecular diagnostics outfit Biodesix has come close to doubling a Series E financing that it first announced in December. The company, which is developing a personalized medicine-focused lung cancer test, initially raised $8.3 million for the round in a mix of both new funding and the conversion of a convertible note. But Biodesix has now pulled in another $6.1 million from a follow-on sale of preferred shares. Execs plan on using the now-$14.4 million cash infusion to help advance its VeriStrat serum protein test that helps physicians figure out the best treatment for patients with advanced non-small cell lung cancer. Item